{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T05:51:43Z","timestamp":1790920303827,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2005,1,1]],"date-time":"2005-01-01T00:00:00Z","timestamp":1104537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2005,1]]},"DOI":"10.1016\/j.autrev.2004.06.001","type":"journal-article","created":{"date-parts":[[2004,7,23]],"date-time":"2004-07-23T19:10:35Z","timestamp":1090609835000},"page":"28-34","source":"Crossref","is-referenced-by-count":22,"title":["TNF-\u03b1 inhibitors in systemic vasculitides and connective tissue diseases"],"prefix":"10.1016","volume":"4","author":[{"given":"Peter","family":"Lamprecht","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2004.06.001_bib1","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/S0952-7915(02)00397-7","article-title":"Therapy of autoimmune diseases: clinical trials and new biologics","volume":"14","author":"Nepom","year":"2002","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.autrev.2004.06.001_bib2","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nm0395-211","article-title":"Multiple sclerosis: TNF revisited, with promise","volume":"1","author":"Raine","year":"1995","journal-title":"Nature Med."},{"key":"10.1016\/j.autrev.2004.06.001_bib3","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1056\/NEJM199108153250704","article-title":"Association between tumor necrosis factor-\u03b1 and disease progression in patients with multiple sclerosis","volume":"325","author":"Sharief","year":"1991","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.autrev.2004.06.001_bib4","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1002\/eji.1830240916","article-title":"Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF-receptor-immunoglobulin fusion proteins","volume":"24","author":"Baker","year":"1994","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.autrev.2004.06.001_bib5","doi-asserted-by":"crossref","first-page":"11294","DOI":"10.1073\/pnas.92.24.11294","article-title":"Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor \u03b1","volume":"92","author":"Probert","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.autrev.2004.06.001_bib6","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1056\/NEJMcibr035136","article-title":"Molecular mimicry in multiple sclerosis","volume":"349","author":"Wekerle","year":"2003","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.autrev.2004.06.001_bib7","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1212\/WNL.47.6.1531","article-title":"Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2","volume":"47","author":"Van","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2004.06.001_bib8","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1212\/WNL.53.3.457","article-title":"TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The lenercept multiple sclerosis study group and the University of British Columbia MS\/MRI analysis group","volume":"53","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2004.06.001_bib9","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nm0198-078","article-title":"TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination","volume":"4","author":"Liu","year":"1998","journal-title":"Nature Med."},{"key":"10.1016\/j.autrev.2004.06.001_bib10","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1191\/096120398678919949","article-title":"Renal expression of IL-6 and TNF-\u03b1 genes in lupus nephritis","volume":"7","author":"Herrera-Esparza","year":"1998","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2004.06.001_bib11","first-page":"LB08","article-title":"TNF\u03b1 is an essential mediator in lupus nephritis","volume":"46","author":"Aringer","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.autrev.2004.06.001_bib12","first-page":"S97","article-title":"Experience with infliximab in the treatment of mixed connective tissue disease\/lupus","volume":"61","author":"Scott","year":"2002","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.autrev.2004.06.001_bib13","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s00393-003-0530-y","article-title":"Gibt es eine Indikation f\u00fcr TNF\u03b1-Antagonisten bei Kollagenosen?","volume":"62","author":"Manger","year":"2003","journal-title":"Z. Rheumtol."},{"key":"10.1016\/j.autrev.2004.06.001_bib14","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1002\/1529-0131(200011)43:11<2383::AID-ANR2>3.0.CO;2-D","article-title":"Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor \u03b1. Findings in open-label and randomized placebo-controlled trials","volume":"43","author":"Charles","year":"2000","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.autrev.2004.06.001_bib15","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0140-6736(02)07714-0","article-title":"Drug-induced systemic lupus erythematosus associated with etanercept therapy","volume":"359","author":"Shakoor","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2004.06.001_bib16","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/1529-0131(200101)44:1<186::AID-ANR25>3.0.CO;2-B","article-title":"Immunomodulatory effects of anti-tumor necrosis factor \u03b1 therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study","volume":"44","author":"Baeten","year":"2001","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.autrev.2004.06.001_bib17","first-page":"131","article-title":"Tumor necrosis factor-alpha and receptors for it in labial salivary glands in Sj\u00f6gren's syndrome","volume":"19","author":"Koski","year":"2001","journal-title":"Clin. Exp. Rheumatol."},{"issue":"Suppl. 9","key":"10.1016\/j.autrev.2004.06.001_bib18","first-page":"S403","article-title":"Treatment with pegylated recombinant mthionyl human soluble tumor necrosis factor type I receptor prevents development of Sj\u00f6gren's syndrome and diabetes in the NOD mouse model","volume":"42","author":"Tornwall","year":"1999","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.autrev.2004.06.001_bib19","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/art.20146","article-title":"Inefficacy of infliximab in primary Sj\u00f6gren's syndrome. Results of the randoized, controlled trial of remicade in primary Sj\u00f6gren's syndrome (TRIPSS)","volume":"50","author":"Mariette","year":"2004","journal-title":"Arthritis Rheum."},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2004.06.001_bib20","first-page":"OP0057","article-title":"Etanercept in the treatment of primary Sj\u00f6gren's syndrome: a pilot study","volume":"62","author":"Zandbelt","year":"2003","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.autrev.2004.06.001_bib21","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1007\/s100670070027","article-title":"Elevation of serum tumour necrosis factor receptors in patients with polymyositis and dermatomyositis","volume":"19","author":"Shimizu","year":"2000","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.autrev.2004.06.001_bib22","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s004010051165","article-title":"Tumor necrosis factor-alpha expression in muscles of polymyositis and dermatomyositis","volume":"99","author":"Kuru","year":"2000","journal-title":"Acta Neuropathol. (Berl)"},{"key":"10.1016\/j.autrev.2004.06.001_bib23","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s00401-002-0635-4","article-title":"Expression of tumor necrosis factor-alpha in regenerating muscle fibers in inflammatory and non-inflammatory myopathies","volume":"105","author":"Kuru","year":"2003","journal-title":"Acta Neuropathol. (Berl)"},{"key":"10.1016\/j.autrev.2004.06.001_bib24","doi-asserted-by":"crossref","first-page":"515","DOI":"10.4049\/jimmunol.169.1.515","article-title":"An autoreactive \u03b3\u03b4 TCR derived from a polymyositis lesion","volume":"169","author":"Wiendly","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.autrev.2004.06.001_bib25","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/rheumatology\/keh079","article-title":"Refractory polymyositis responding to infliximab: extended follow-up","volume":"43","author":"Labioche","year":"2004","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2004.06.001_bib26","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1056\/NEJMra022694","article-title":"Medium- and large vessel vasculitis","volume":"349","author":"Weyand","year":"2003","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.autrev.2004.06.001_bib27","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1016\/S0002-9440(10)64458-6","article-title":"Trapping of misdirected dendritic cells in the granulomatous lesions of giant cell arteritis","volume":"161","author":"Krupa","year":"2002","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.autrev.2004.06.001_bib28","first-page":"1925","article-title":"Interferon-\u03b3-producing T cells in giant cell vasculitis represent a minority of tissue-infiltrating cell and are located distant from the site of pathology","volume":"148","author":"Wagner","year":"1996","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.autrev.2004.06.001_bib29","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1093\/rheumatology\/keh058","article-title":"Tissue production of pro-inflammatory cytokines (IL-1\u03b2, TNF-\u03b1, and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteriitis","volume":"43","author":"Hernandez-Rodriguez","year":"2004","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2004.06.001_bib30","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/rheumatology\/41.3.347","article-title":"Anti tumor necrosis factor treatment with infliximab in a case of giant cell arteritis resistant to steroid and immunosuppressive drugs","volume":"41","author":"Airo","year":"2002","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2004.06.001_bib31","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1136\/ard.62.4.373","article-title":"Successful treatment of resistant giant cell arteritis with etanercept","volume":"62","author":"Tan","year":"2003","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.autrev.2004.06.001_bib32","first-page":"469","article-title":"Treatment of resistant giant cell arteritis with etanercept","volume":"63","author":"Docken","year":"2004","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.autrev.2004.06.001_bib33","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/1529-0131(200102)44:2<469::AID-ANR66>3.0.CO;2-0","article-title":"Elevated interleukin-4 and interleukin-13 production by T cell lines from patients with Churg\u2013Strauss syndrome","volume":"44","author":"Kiene","year":"2001","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.autrev.2004.06.001_bib34","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/s00393-003-0527-6","article-title":"Der Einsatz von TNF\u03b1-Antagonisten bei prim\u00e4r systemischen Vaskulitiden","volume":"62","author":"Gause","year":"2003","journal-title":"Z. Rheumatol."},{"key":"10.1016\/j.autrev.2004.06.001_bib35","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/art.10847","article-title":"Down-regulation of the non-specific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab","volume":"48","author":"Zou","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.autrev.2004.06.001_bib36","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1136\/ard.62.6.561","article-title":"Up regulation of the production of tumor necrosis factor \u03b1 and interferon \u03b3 by T cells in ankylosing spondylitis during treatment with etanercept","volume":"62","author":"Zou","year":"2003","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.autrev.2004.06.001_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1521-6616(03)00121-9","article-title":"Differences in CCR5 expression on peripheral blood CD4+CD28\u2212 T-cells and in granulomatous lesions between localized and generalized Wegener's granulomatosis","volume":"108","author":"Lamprecht","year":"2003","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.autrev.2004.06.001_bib38","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1016\/S0002-9440(10)61118-2","article-title":"Peripheral blood and granuloma CD4+CD28\u2212 T-cells are a major source of IFN-\u03b3 and TNF-\u03b1 in Wegerner's granulomatosis","volume":"160","author":"Komocsi","year":"2002","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.autrev.2004.06.001_bib39","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1111\/j.1523-1755.2004.501_5.x","article-title":"CD28\u2212 T cells display features of effector memory T cells in Wegener's granulomatosis","volume":"65","author":"Lamprecht","year":"2004","journal-title":"Kidney Int."},{"key":"10.1016\/j.autrev.2004.06.001_bib40","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jaut.2003.10.008","article-title":"Frequency of proteinase 3 (PR3)-specific autoreactive T-cells determined by cytokine flow cytometry in Wegener's granulomatosis","volume":"22","author":"Winek","year":"2004","journal-title":"J. Autoimmun."}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997204000874?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997204000874?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T21:08:03Z","timestamp":1585861683000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997204000874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,1]]}},"alternative-id":["S1568997204000874"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2004.06.001","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2005,1]]}}}